मिल्नासिप्रान के इंटरैक्शन

• Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with milnacipran hydrochloride or within 5 days of stopping treatment with milnacipran hydrochloride. (मिल्नासिप्रान लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome Selective-serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), including milnacipran hydrochloride, can precipitate serotonin syndrome, a potentially life-threatening condition. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Anticoagulants, Antiplatelets, Thrombolytics, and Selective Serotonin Reuptake Inhibitors (SSRIs)/Serotonin Norepinephrine Reuptake Inhibitors (SNRIs): Avoid concomitant use due to increased risk of bleeding. (एडोक्साबैन लेबल, दवाओं के इंटरैक्शन)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Serotonergic Drugs Serotonin syndrome can occur with use of milnacipran hydrochloride and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. (मिल्नासिप्रान लेबल, दवाओं के इंटरैक्शन)

Serotonergic Drugs Serotonin syndrome can occur with use of milnacipran hydrochloride and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. (मिल्नासिप्रान लेबल, दवाओं के इंटरैक्शन)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (ऑक्सीकोडोन लेबल, दवाओं के इंटरैक्शन)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ऑक्सीमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ओलिसेरिडिन लेबल, दवाओं के इंटरैक्शन)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (कोडीन लेबल, दवाओं के इंटरैक्शन)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (ज़िप्रासिडोन लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with milnacipran hydrochloride or within 5 days of stopping treatment with milnacipran hydrochloride. (मिल्नासिप्रान लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Avoid co-administration of milnacipran hydrochloride and intravenous digoxin [see Warnings and Precautions ( 5.3 , 5.4 )] . (मिल्नासिप्रान लेबल, दवाओं के इंटरैक्शन)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Serotonergic Drugs The concomitant use of dextroamphetamine sulfate and serotonergic drugs increases the risk of serotonin syndrome. (डेक्सट्रोएम्फेटामाइन लेबल, दवाओं के इंटरैक्शन)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (पेंटाज़ोसिन और नालोक्सोन लेबल, सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (पैरासिटामोल और कोडीन लेबल, सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (प्रोमेथाज़िन और कोडीन लेबल, दवाओं के इंटरैक्शन)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (फेंटानिल लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with milnacipran hydrochloride or within 5 days of stopping treatment with milnacipran hydrochloride. (मिल्नासिप्रान लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Serotonergic Drugs Serotonin syndrome can occur with use of milnacipran hydrochloride and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. (मिल्नासिप्रान लेबल, दवाओं के इंटरैक्शन)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (बेलाडोना और ओपियम लेबल, दवाओं के इंटरैक्शन)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ब्यूटाल्बिटल, एस्पिरिन, कैफीन और कोडीन लेबल, दवाओं के इंटरैक्शन)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (ब्यूटाल्बिटल, पैरासिटामोल, कैफीन और कोडीन लेबल, दवाओं के इंटरैक्शन)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (ब्यूटॉर्फेनॉल लेबल, सावधानियां)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (ब्यूप्रेनॉर्फिन लेबल, दवाओं के इंटरैक्शन)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (ब्यूप्रेनॉर्फिन और नालोक्सोन लेबल, दवाओं के इंटरैक्शन)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

In addition, do not start milnacipran hydrochloride in a patient who is being treated with linezolid or intravenous methylene blue ( 4.1 , 5.2 ). (मिल्नासिप्रान लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (मेटाक्सालोन लेबल, दवाओं के इंटरैक्शन)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (मेथएम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (मेथाडोन लेबल, चेतावनियां और सावधानियां)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (मॉर्फिन लेबल, दवाओं के इंटरैक्शन)

• Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with milnacipran hydrochloride or within 5 days of stopping treatment with milnacipran hydrochloride. (मिल्नासिप्रान लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (रेमिफेंटानिल लेबल, चेतावनियां और सावधानियां)

Serotonergic Drugs Serotonin syndrome can occur with use of milnacipran hydrochloride and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. (मिल्नासिप्रान लेबल, दवाओं के इंटरैक्शन)

In addition, do not start milnacipran hydrochloride in a patient who is being treated with linezolid or intravenous methylene blue ( 4.1 , 5.2 ). (मिल्नासिप्रान लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (लिसडेक्सएम्फेटामाइन लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (लेवॉर्फेनॉल लेबल, सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Serotonin Syndrome Selective-serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), including milnacipran hydrochloride, can precipitate serotonin syndrome, a potentially life-threatening condition. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Avoid concomitant use of milnacipran hydrochloride in patients with substantial alcohol use or chronic liver disease ( 5.6 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

सेंट जॉन्स वॉर्ट को एंटीडिप्रेसेंट और अन्य सेरोटोनर्जिक दवाओं के साथ लेने से सेरोटोनिन सिंड्रोम का जोखिम बढ़ता है। (NCCIH, St. John's Wort)

• Serotonin Syndrome and MAOIs: Do not use MAOIs intended to treat psychiatric disorders with milnacipran hydrochloride or within 5 days of stopping treatment with milnacipran hydrochloride. (मिल्नासिप्रान लेबल, निषेध (कॉन्ट्राइंडिकेशन))

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (हाइड्रोकोडोन लेबल, दवाओं के इंटरैक्शन)

S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और आइबुप्रोफेन लेबल, सावधानियां)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (हाइड्रोकोडोन और क्लोरफेनिरामिन लेबल, दवाओं के इंटरैक्शन)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (हाइड्रोकोडोन और पैरासिटामोल लेबल, सावधानियां)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (हाइड्रोकोडोन और होमाट्रोपिन लेबल, दवाओं के इंटरैक्शन)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (हाइड्रोमॉर्फोन लेबल, दवाओं के इंटरैक्शन)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Therefore, concomitant use of milnacipran hydrochloride with epinephrine and norepinephrine may be associated with paroxysmal hypertension and possible arrhythmia [see Warnings and Precautions ( 5.3 , 5.4 )] . (मिल्नासिप्रान लेबल, दवाओं के इंटरैक्शन)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Therefore, concomitant use of milnacipran hydrochloride with epinephrine and norepinephrine may be associated with paroxysmal hypertension and possible arrhythmia [see Warnings and Precautions ( 5.3 , 5.4 )] . (मिल्नासिप्रान लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Drugs that Interfere with Hemostasis Concomitant use of milnacipran hydrochloride with an antiplatelet or anticoagulant drug (e.g., NSAIDs, aspirin, and warfarin) may potentiate the risk of bleeding. (मिल्नासिप्रान लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Drugs that Interfere with Hemostasis Concomitant use of milnacipran hydrochloride with an antiplatelet or anticoagulant drug (e.g., NSAIDs, aspirin, and warfarin) may potentiate the risk of bleeding. (मिल्नासिप्रान लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Drugs that Interfere with Hemostasis Concomitant use of milnacipran hydrochloride with an antiplatelet or anticoagulant drug (e.g., NSAIDs, aspirin, and warfarin) may potentiate the risk of bleeding. (मिल्नासिप्रान लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Drugs that Interfere with Hemostasis Concomitant use of milnacipran hydrochloride with an antiplatelet or anticoagulant drug (e.g., NSAIDs, aspirin, and warfarin) may potentiate the risk of bleeding. (मिल्नासिप्रान लेबल, दवाओं के इंटरैक्शन)

Drugs that Interfere with Hemostasis Concomitant use of milnacipran hydrochloride with an antiplatelet or anticoagulant drug (e.g., NSAIDs, aspirin, and warfarin) may potentiate the risk of bleeding. (मिल्नासिप्रान लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Drugs that Interfere with Hemostasis Concomitant use of milnacipran hydrochloride with an antiplatelet or anticoagulant drug (e.g., NSAIDs, aspirin, and warfarin) may potentiate the risk of bleeding. (मिल्नासिप्रान लेबल, दवाओं के इंटरैक्शन)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system… (नालबुफिन लेबल, दवाओं के इंटरैक्शन)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Drugs that Interfere with Hemostasis Concomitant use of milnacipran hydrochloride with an antiplatelet or anticoagulant drug (e.g., NSAIDs, aspirin, and warfarin) may potentiate the risk of bleeding. (मिल्नासिप्रान लेबल, दवाओं के इंटरैक्शन)

Therefore, concomitant use of milnacipran hydrochloride with epinephrine and norepinephrine may be associated with paroxysmal hypertension and possible arrhythmia [see Warnings and Precautions ( 5.3 , 5.4 )] . (मिल्नासिप्रान लेबल, दवाओं के इंटरैक्शन)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Therefore, concomitant use of milnacipran hydrochloride with epinephrine and norepinephrine may be associated with paroxysmal hypertension and possible arrhythmia [see Warnings and Precautions ( 5.3 , 5.4 )] . (मिल्नासिप्रान लेबल, दवाओं के इंटरैक्शन)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Therefore, concomitant use of milnacipran hydrochloride with epinephrine and norepinephrine may be associated with paroxysmal hypertension and possible arrhythmia [see Warnings and Precautions ( 5.3 , 5.4 )] . (मिल्नासिप्रान लेबल, दवाओं के इंटरैक्शन)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Drugs that Interfere with Hemostasis Concomitant use of milnacipran hydrochloride with an antiplatelet or anticoagulant drug (e.g., NSAIDs, aspirin, and warfarin) may potentiate the risk of bleeding. (मिल्नासिप्रान लेबल, दवाओं के इंटरैक्शन)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Caution patients about the risk of bleeding associated with the concomitant use of milnacipran hydrochloride and NSAIDs, aspirin, or other drugs that affect coagulation ( 5.9 ). (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anticoagulants may add to this risk. (मिल्नासिप्रान लेबल, चेतावनियां और सावधानियां)

Serotonergic Drugs Serotonin syndrome can occur with use of milnacipran hydrochloride and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. (मिल्नासिप्रान लेबल, दवाओं के इंटरैक्शन)

Serotonergic Drugs Serotonin syndrome can occur with use of milnacipran hydrochloride and other serotonergic drugs (other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. (मिल्नासिप्रान लेबल, दवाओं के इंटरैक्शन)

Clonidine: Because milnacipran hydrochloride inhibits norepinephrine reuptake, co-administration with clonidine may inhibit clonidine’s anti-hypertensive effect. (मिल्नासिप्रान लेबल, दवाओं के इंटरैक्शन)

Clinical Impact Although no clinically significant drug interactions with adjunctive SSRI/SNRIs in MDD were observed in CAPLYTA clinical trials, CAPLYTA’s moderate serotonin transporter (SERT) activity may increase the risk of SRI-associated adverse reactions (e.g., serotonin syndrome, hyponatremia). * See www.fda.gov/CYPandTransporterInteractingDrugs for examples… (लुमाटेपेरोन लेबल, दवाओं के इंटरैक्शन)